Introduction: With regards to depression, the role of N-methyl-D-aspartate receptor (NMDA)
was pursued many years ago, mainly in the form of preclinical studies. Since then, there …

Depression is a psychiatric disorder that affects millions of people worldwide. Individuals
battling this disorder commonly experience high rates of relapse, persistent residual …

Depression is a major public health concern that affects∼ 5% of the population in
industrialized societies in any given year. Drugs that increase the synaptic availability of …

Context Existing therapies for major depression have a lag of onset of action of several
weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have …

BACKGROUND: Research studies suggest that glutamate dysfunction, in particular N-
methyl-d-aspartate receptors (NMDARs) abnormalities, may be involved in the …

Emerging evidence indicates that non‐monominergic drugs could hold promise as novel
antidepressants, particularly in the case of treatment resistance. Particular attention has …

Introduction: Current antidepressant therapies exhibit low therapeutic efficiency and delayed
onset of antidepressant action. Thus, the search for better acting agents is a continuous …

Introduction: Mood disorders, including depression, are becoming increasingly prevalent in
the developed world. Furthermore, treatment of depression therapeutics, mainly influencing …

Background Ketamine has rapid-acting antidepressant effects but is associated with
psychotomimetic and other adverse effects. A 7-chlorokynurenic acid is a potent and specific …

Since the discovery that a single dose of ketamine, an N-methyl-D-aspartate receptor
(NMDAR) antagonist, had rapid and long-lasting antidepressant effects, there has been …